NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Down 84.0% in December

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) saw a large drop in short interest in December. As of December 31st, there was short interest totaling 372 shares, a drop of 84.0% from the December 15th total of 2,321 shares. Based on an average daily volume of 41,776 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 41,776 shares, the short-interest ratio is presently 0.0 days.

NRx Pharmaceuticals Stock Performance

Shares of NRXPW traded up $0.00 during midday trading on Monday, hitting $0.06. The company had a trading volume of 3,914 shares, compared to its average volume of 11,259. NRx Pharmaceuticals has a 1 year low of $0.04 and a 1 year high of $0.37. The company’s 50-day simple moving average is $0.08 and its 200-day simple moving average is $0.09.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.

Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.